ChanTest sets the standard in preclinical cardiac risk assessment

We design our comprehensive range of ion channel assays, follow-up models, and consultation services to give you the early answers you need to identify the most-promising drug targets, and eliminate those that could be harmful – before you invest millions on clinical trials.
Click on the PDF icons below to download information sheets on our discovery assays.

	General profiling assays:
	Channel Panels – by organ or therapeutic area Cardiac Channel Panel CNS Channel Panel Pain Channel Panel
	Ion Channel Catalog – the broadest list of validated ion channels available
	FASTPatch moderate-throughput screening – tabular results, ranked to identify the safety of drug candidates
	Super FASTPatch high-throughput screening – tabular results, ranked to identify the safety of drug candidates
	FLIPR highest-throughput screening – measures thallium membrane potential, calcium concentration for calcium-permeant channels and potassium (thallium) flux for voltage-gated and calcium-activated potassium channels
	Ranking within profiles – multi-concentration/compound screens:
	One channel FASTPatch moderate-throughput screen – tabular results, ranked to identify the safety of drug candidates
	One channel Super FASTPatch high-throughput screen – tabular results, ranked to identify the safety of drug candidates
	Multi-channel FASTPatch moderate-throughput screen – tabular results, ranked to identify the safety of drug candidates
	Multi-channel Super FASTPatch high-throughput screen – tabular results, ranked to identify the safety of drug candidates
	Ranking within profiles – additional screens:
	HERG-Lite screen – economically identifies hidden hERG trafficking inhibition
	FAST & Lite (FASTPatch® & HERGLite®) – Provides a comprehensive valuation of hERG inhibition – both direct block & defective trafficking
	hERG 450 – Identifies drug-drug interaction risk